Tuesday 24 May
Debate session
-
Danilo Norata
Danilo Norata
Milano, ItalyGiuseppe Danilo Norata, Prof, PhD, is Full Professor of Pharmacology at the University of Milan, Italy, and is Honorary Senior Lecturer at the William Harvey Research Institute, Barts and The London School of Medicine & Dentistry Queen Mary University, London, UK. He graduated in 1996 in Pharmacy, received the PhD in Experimental Medicine at the University of Siena in 2002 and was a post-doc from 2002 to 2004 at the Karolinska Institute in Stockholm, Sweden. His research activity is devoted to the investigation of molecular mechanisms involved in vascular and cardiometabolic diseases and their connection with immunometabolism from a translational perspective. He coordinates the activities at the Laboratory of Lipoproteins, Atherosclerosis and Immunity at the Department of Pharmacological and Biomolecular Sciences in Milan and those of the Laboratory of Cardiovascular Genetics and Genomics at the Center for The Study of Atherosclerosis at the Bassini Hospital. He published more than 16 papers in the field of cardiovascular and immunometabolic diseases and participated as speaker and/or chairmen in several national and international meetings. Giuseppe Danilo Norata is Academic Editor of PLOS ONE and is a member of the Editorial Board of Nutrition Metabolism and Cardiovascular Disease. He is a member of the European Lipoprotein Club Organizing Committee, of the Faculty of the International Atherosclerosis Research School and of the European Working Group on Immunometabolism.
- Stefano Romeo
Anne Tybjaerg Hansen, Copenhagen, Denmark
Arnold von Eckardstein, Zurich, Switzerland
Arnold von Eckardstein
ZurichSwitzerland
Arnold von Eckardstein studied medicine in Giessen and Kiel and then specialized in laboratory medicine and clinical chemistry in Frankfurt and Münster (Germany). Since 2001, he is professor at the medical faculty of the University of Zurich and the director of the Institute of Clinical Chemistry of the University Hospital of Zurich (Switzerland; http://www.en.ikc.usz.ch/Pages/default.aspx). His main research interests include risk factors and biomarkers of cardiovascular and metabolic diseases as well as structure, function, and metabolism of high density lipoproteins (HDL) and sphingolipids. He has published about 400 original and review papers in international peer reviewed scientific journals. Arnold von Eckardstein is the Editor-in-Chief of Atherosclerosis and current member of the Editorial Boards of Arteriosclerosis, Thrombosis and Vascular Biology; BBA Molecular Biology of Lipids; Cardiovascular Research, and European Heart Journal. Previously, he served as the Chairman of the European Lipoprotein Club, the Swiss and German Atherosclerosis Societies, and the Swiss Society of Clinical Chemistry as well as the Secretary of the European Atherosclerosis Society.
Wednesday 25 May
Young fellows’ session
-
Christoph Binder
Christoph Binder
Vienna, AustriaChristoph J. Binder (born 1973) received his MD degree from the University of Vienna, Austria, in 1997 and his PhD degree in Molecular Pathology from the University of California San Diego (UCSD), USA, in 2002. Following postdoctoral training at the Department of Medicine of UCSD, he established his own research group at the Medical University of Vienna in 2005. In 2009 he was appointed Full Professor of Atherosclerosis Research at the Medical University of Vienna. He is a specialist in Laboratory Medicine and currently Deputy Head of the Department of Laboratory Medicine at the Medical University of Vienna. He is also PI of the Austrian Familial Hypercholesterolemia Registry. Since 2014 Christoph Binder acts as a referee and board member of the Austrian Science Fund. From 2016 until 2019 he was a member of the Executive Committee and since 2021 he is Vice President of the European Atherosclerosis Society. Christoph Binder’s research interests span vascular biology, lipid oxidation, and immunity. His group is investigating immune mechanisms of atherosclerosis with a special focus on the role of innate and humoral immunity and how this can be exploited for the treatment of cardiovascular disease. Christoph Binder has authored >150 original and review papers in important international journals, including Nature Medicine and Nature. He is Co-Editor of Atherosclerosis and Section Editor of Thrombosis & Haemostasis.
- Jan Boren
Chrysoula Boutari, Greece
Karin Bornfeldt, Washington, USA
Jeffrey Kroon, Amsterdam, The Netherlands
Laurent Yvant-Charvet, Nice, France
Laurent Yvant-Charvet
NiceFrance
Dr. Laurent Yvan-Charvet obtained his Ph.D. in Endocrinology in 2005 from the University of Paris XI, France. His research work at Columbia University has been mainly focused on how regulation of inflammation and stem cell biology by cholesterol efflux pathways affect cardiovascular diseases. He was the recipient of the Roger Davis Award in 2010, finalist of the I.H. Page Young Investigator Award in 2011, recipient of the EAS young Investigator Award in 2013 and the Daniel Steinberg Early Career Investigator Award in 2015. After a contribution to the development of new therapeutics for cardiovascular diseases at Pfizer, his current research interest as a Director of Research and group leader lies in hematopoietic cell metabolism – a new area of research for cardiovascular and inflammatory diseases. This work is supported by two most prominent French and European fundings: an Atip-Avenir excellence program and an European ERC consolidator excellence program.
